Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma
Albert Jang, Miguel Muniz, Megan Spychalla, Timothy Burns, Amrit Singh, Elisabeth I Heath, Brian A Costello, Jacob J Orme, J Fernando Quevedo, Daniel S Childs, Lance C Pagliaro, Nicola Normanno · 2026
Read Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma by Albert Jang, Miguel Muniz, Megan Spychalla, Timothy Burns, Amrit Singh, Elisabeth I Heath, Brian A Costello, Jacob J Orme, J Fernando Quevedo, Daniel S Childs, Lance C Pagliaro, Nicola Normanno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13424796.txt.
Description
Jang and colleagues reviewed in 2026 a chemotherapy pairing for bladder-area cancer that had grown worse on immunotherapy. The cancer, metastatic urothelial carcinoma, had spread and had progressed despite immune checkpoint inhibitors, drugs that free the immune system to attack tumours. Their team studied 32 Mayo Clinic patients treated from 2018 to 2024 with paclitaxel plus carboplatin, mostly alongside continued immunotherapy.
About four in ten patients saw their tumours shrink, and three in four gained disease control for a time. The middle survival time was just over nine months, and the middle time before growth resumed was under five months. Side effects matched the known profile of these drugs and were mostly manageable. The authors call the pairing promising after immunotherapy failure, while urging tests in larger groups before firm guidance.
Catalog record
| CREATOR | Albert Jang, Miguel Muniz, Megan Spychalla, Timothy Burns, Amrit Singh, Elisabeth I Heath, Brian A Costello, Jacob J Orme, J Fernando Quevedo, Daniel S Childs, Lance C Pagliaro, Nicola Normanno |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |